Genomic Instability
DNA damage accumulates over time from radiation, metabolic byproducts, and replication errors. Antioxidants, DNA repair pathways.
The science of aging, what interventions work, and where research peptides fit in the bigger picture
Last updated: April 2026 | Not medical advice
The science of aging has advanced more in the past decade than in the previous century. We now understand many of the molecular mechanisms that drive biological aging — the "hallmarks of aging" identified by López-Otín and colleagues. This understanding has opened the door to targeted interventions: lifestyle changes, pharmaceuticals, and increasingly, research peptides that address specific aging pathways.
This guide summarizes the state of that science, ranks interventions by evidence quality, and explains where research peptides fit — both what they can plausibly do and where the evidence falls short.
The goal of modern aging research has shifted. Adding years to life that are spent in frailty, disease, or cognitive decline is not the aim. The focus is on healthspan — the years of healthy, functional, high-quality life — and on "compressing morbidity" (shortening the period of decline before death).
López-Otín et al. (2013, updated 2023) identified 12 molecular "hallmarks" — biological changes that drive aging. Understanding these hallmarks tells us precisely where targeted interventions might work.
DNA damage accumulates over time from radiation, metabolic byproducts, and replication errors. Antioxidants, DNA repair pathways.
Telomeres shorten with each cell division → cellular senescence. Epithalon targets this via telomerase activation.
Gene expression patterns drift with age. Methylation clocks (Horvath) measure biological age through epigenetic changes.
Protein folding and clearance decline → misfolded proteins accumulate. Linked to neurodegeneration (Alzheimer's, Parkinson's).
mTOR, AMPK, IGF-1 signaling dysregulation. Addressed by caloric restriction, metformin, and indirectly by GLP-1 agonists.
Energy production declines with age. Exercise is the most evidence-backed mitochondrial health intervention.
Senescent ("zombie") cells accumulate, releasing inflammatory signals (SASP). Senolytics research is an active pharmaceutical field.
Regenerative capacity declines as stem cell pools diminish. GH peptides indirectly support tissue regeneration via IGF-1.
Hormonal and signaling changes alter cell-to-cell communication. GHK-Cu influences gene expression through this pathway.
Low-grade, sterile inflammation accumulates with age. BPC-157, Selank, GHK-Cu have anti-inflammatory research profiles.
Gut microbiome diversity and composition decline. BPC-157 has direct gut protective research in animal models.
Cellular self-cleaning (autophagy) declines with age. Exercise and caloric restriction are the strongest autophagy stimulants.
Not all healthy aging interventions have equal support. The following grid ranks them honestly by strength of human evidence.
Preserves muscle mass, bone density, insulin sensitivity, cognitive function. Multiple large RCTs and longitudinal studies. Strongest intervention for all-cause mortality.
Evidence: Very HighVO2max is the single best predictor of all-cause mortality in adults. Even modest aerobic fitness improvements produce large mortality benefits. Extensive human evidence.
Evidence: Very HighPoor sleep is associated with Alzheimer's pathology (amyloid/tau clearance happens during sleep), cardiovascular disease, metabolic dysfunction, and reduced immune function.
Evidence: Very HighMediterranean-style diet has the strongest evidence base. Protein adequacy (1.6–2.2g/kg for muscle maintenance) is particularly underappreciated. Caloric restriction extends lifespan in most model organisms.
Evidence: HighObesity and metabolic syndrome dramatically accelerate biological aging through inflammation, insulin resistance, and cardiovascular disease pathways. GLP-1 agonists are now the strongest pharmaceutical intervention for this.
Evidence: HighEmerging evidence beyond weight loss — cardiovascular mortality reduction, possible neurodegeneration protection, anti-inflammatory effects. Semaglutide showed 20% reduction in cardiovascular events (SELECT trial).
Evidence: High (and growing)Addresses age-related GH decline (somatopause). Sermorelin has the most developed clinical record. Evidence supports body composition improvements; long-term longevity benefits not established in humans.
Evidence: ModerateActivates telomerase. 12-year human study (Khavinson) showed mortality reduction. Methodologically limited but uniquely long longitudinal data for a research peptide.
Evidence: Moderate (long-term human data exists)Strong animal model evidence for repair. Limited but emerging human data (BPC-157 IBD trials). Addresses the declining regenerative capacity of aging tissue.
Evidence: Moderate (animal strong; human limited)Endogenous peptide that declines with age. Influences ~4,000 genes. Strong in vitro and cosmetic evidence. Limited systemic human trial data.
Evidence: Moderate (mechanistic strong; systemic human limited)NAD+ declines with age. NMN and NR raise NAD+ in human trials. Downstream benefits on energy metabolism and DNA repair are mechanistically plausible. Clinical outcome data is still early.
Evidence: Moderate (biomarker data; outcome data early)AMPK activator / mTOR inhibitor. Extensive observational data suggesting reduced age-related disease. Formal longevity RCT (TAME) underway. Currently used as diabetes/pre-diabetes drug.
Evidence: Moderate (observational strong; longevity RCT pending)The optimal strategies for healthy aging shift with age. What matters most in your 30s is different from your 50s or 70s — both in terms of what's declining and what interventions have the best leverage.
This decade is about establishing habits before significant decline begins. Focus: resistance training habit formation, aerobic fitness baseline (VO2max is already declining after ~25), avoiding metabolic damage (processed food, excess alcohol), sleep hygiene. Research peptides are rarely the leverage point here — lifestyle is. GLP-1 agonists may be relevant if obesity or insulin resistance are already present.
GH secretion has declined ~30% from peak. Muscle loss begins to accelerate without deliberate resistance training. Metabolic syndrome risk rises. Sleep architecture begins to change. First decade where GH peptides become relevant: Sermorelin or CJC-1295/Ipamorelin can restore something closer to 30-year-old GH patterns. Metabolic management (GLP-1 agonists if appropriate) pays compounding dividends.
Somatopause is well established. Telomere shortening becomes more clinically relevant. For women, menopause adds hormonal complexity. BPC-157 and TB-500 become more relevant as healing slows. Epithalon cyclic protocols gain relevance. Serious longevity researchers begin tracking biological age markers (methylation clocks, telomere length). Cardiovascular risk management becomes critical.
The primary goal shifts to maintenance of existing function. Muscle mass preservation is critical — sarcopenia accelerates. GH peptides, GHK-Cu, and Epithalon address multiple aging mechanisms simultaneously. Physical therapy-adjacent recovery tools (BPC-157, TB-500) become highly relevant as injury recovery slows. Cognitive maintenance (Semax for BDNF, Selank for stress response and neuroinflammation) enters the picture. Social connection and purpose become increasingly important determinants of healthspan.
| Peptide | Primary Aging Hallmark(s) Targeted | Key Benefit Area | Evidence Level | Price Guide |
|---|---|---|---|---|
| Epithalon | Telomere attrition | Telomere length, melatonin normalization | Human (12-yr study) | → Guide |
| GHK-Cu | Altered intercellular communication, ECM | Collagen, gene expression reset, antioxidant | In vitro + cosmetic human | → Guide |
| BPC-157 | Dysbiosis, stem cell exhaustion, inflammation | Tissue repair, gut health, angiogenesis | Animal strong; limited human | → Guide |
| TB-500 | Stem cell exhaustion, cardiac repair | Muscle/ligament repair, cardiac protection | Animal strong; limited human | → Guide |
| Sermorelin / CJC-1295 | Deregulated nutrient sensing (GH axis) | GH restoration, body composition, sleep | Phase 2/3 (Sermorelin) | → Guide |
| Hexarelin | GH axis + cardiac function (CD36) | Potent GH pulse, direct cardiac protection | Phase 2 (cardiac) | → Guide |
| Semax | Proteostasis (BDNF/NGF upregulation) | Cognitive function, neuroprotection | Phase 2/3 (Russia), drug approved | → Guide |
| Selank | Chronic inflammation, immune dysregulation | Anxiety reduction, neuroinflammation, BDNF | Clinical trials (Russia), drug approved | → Guide |
| Semaglutide / Tirzepatide | Deregulated nutrient sensing, inflammation | Metabolic health, cardiovascular protection | Phase 3 / FDA Approved | → Guide |
The evidence most consistently points to cardiorespiratory fitness (VO2max) as the single strongest predictor of all-cause mortality across age groups — stronger than blood pressure, cholesterol, blood sugar, or BMI. VO2max is modifiable through regular aerobic exercise. A landmark study by Mandsager et al. (2018) found that elite cardiorespiratory fitness (top 25% for age) was associated with 5× lower mortality compared to those with low fitness — a magnitude larger than almost any drug effect studied. Resistance training comes in as a close second for preserving functional independence, muscle mass, and metabolic health.
Several pharmaceutical compounds with peptide-adjacent mechanisms are in longevity trials. Metformin is the subject of the TAME (Targeting Aging with Metformin) trial — the first RCT specifically designed to test a drug for aging itself rather than a specific disease. Rapamycin (an mTOR inhibitor) is being studied in the PEARL trial for aging. GLP-1 agonists like semaglutide are being studied for Alzheimer's disease (EVOKE trial) and Parkinson's disease. For peptides specifically, Epithalon's Khavinson data and BPC-157's IBD trial represent the most developed human datasets, but neither has been subject to modern large-scale RCT methodology for longevity outcomes.
Obesity and metabolic syndrome are among the most powerful accelerants of biological aging. They drive chronic inflammation (inflammaging), insulin resistance, accelerated telomere shortening, cardiovascular damage, and increased cancer risk. Achieving and maintaining a healthy metabolic state may be one of the highest-leverage longevity interventions available. The SELECT trial (Novo Nordisk, 2023) showed semaglutide reduced major cardiovascular events by 20% in non-diabetic obese patients — a result independent of weight loss. Emerging data also suggests GLP-1 agonists may reduce neuroinflammation and potentially dementia risk. The anti-aging implications of these drugs may ultimately extend well beyond weight management.
This is the hard question. Subjective improvements (better sleep, more energy, improved recovery) are real but susceptible to placebo effect. More objective markers include: body composition measurements (DEXA scan for lean mass and fat mass), metabolic markers (fasting insulin, HOMA-IR), inflammatory markers (CRP, IL-6), hormonal markers (IGF-1 for GH axis interventions), and biological age measurements (methylation clocks like TruAge or Dunedin Pace). Tracking these markers before and after a defined protocol period gives much more meaningful data than subjective assessment alone. Consulting with a physician who specializes in longevity medicine can help design an appropriate monitoring strategy.